Related references
Note: Only part of the references are listed.Cancer statistics, 2022
Rebecca L. Siegel et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2022)
Cancer statistics in China and United States, 2022: profiles, trends, and determinants
Changfa Xia et al.
CHINESE MEDICAL JOURNAL (2022)
Inhibiting 31βHSD1 to eliminate the oncogenic effects of progesterone in prostate cancer
Zemin Hou et al.
CELL REPORTS MEDICINE (2022)
Tracing steroidogenesis in prostate biopsy samples to unveil prostate tissue androgen metabolism characteristics and potential clinical application
Zemin Hou et al.
JOURNAL OF STEROID BIOCHEMISTRY AND MOLECULAR BIOLOGY (2021)
Androgens in prostate cancer: A tale that never ends
Zemin Hou et al.
CANCER LETTERS (2021)
Exposure-response analyses of abiraterone and its metabolites in real-world patients with metastatic castration-resistant prostate cancer
M. van Nuland et al.
PROSTATE CANCER AND PROSTATIC DISEASES (2020)
Treatment with abiraterone and enzalutamide does not overcome poor outcome from metastatic castration-resistant prostate cancer in men with the germline homozygous HSD3B1 c.1245C genotype
C. Lu et al.
ANNALS OF ONCOLOGY (2020)
The ChinaMAP analytics of deep whole genome sequences in 10,588 individuals
Yanan Cao et al.
CELL RESEARCH (2020)
HSD3B1 (1245A>C) germline variant and clinical outcomes in metastatic castration-resistant prostate cancer patients treated with abiraterone and enzalutamide: results from two prospective studies
D. J. Khalaf et al.
ANNALS OF ONCOLOGY (2020)
Germline HSD3B1 Genetics and Prostate Cancer Outcomes
Lewis Thomas et al.
UROLOGY (2020)
Functional Silencing of HSD17B2 in Prostate Cancer Promotes Disease Progression
Xiaomei Gao et al.
CLINICAL CANCER RESEARCH (2019)
Association of Missense Polymorphism in HSD3B1 With Outcomes Among Men With Prostate Cancer Treated With Androgen-Deprivation Therapy or Abiraterone
Masaki Shiota et al.
JAMA NETWORK OPEN (2019)
Inhibition of HSP90β Improves Lipid Disorders by Promoting Mature SREBPs Degradation via the Ubiquitin-proteasome System
Zu-Guo Zheng et al.
THERANOSTICS (2019)
Germline Variant in HSD3B1 (1245 A > C) and Response to Abiraterone Acetate Plus Prednisone in Men With New-Onset Metastatic Castration-Resistant Prostate Cancer
Andrew W. Hahn et al.
CLINICAL GENITOURINARY CANCER (2018)
HSD3B1(1245A>C) variant regulates dueling abiraterone metabolite effects in prostate cancer
Mohammad Alyamani et al.
JOURNAL OF CLINICAL INVESTIGATION (2018)
Prospective International Randomized Phase II Study of Low-Dose Abiraterone With Food Versus Standard Dose Abiraterone In Castration-Resistant Prostate Cancer
Russell Z. Szmulewitz et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
Cellular plasticity and the neuroendocrine phenotype in prostate cancer
Alastair H. Davies et al.
NATURE REVIEWS UROLOGY (2018)
Association of HSD3B1 Genotype With Response to Androgen-Deprivation Therapy for Biochemical Recurrence After Radiotherapy for Localized Prostate Cancer
Jason W. D. Hearn et al.
JAMA ONCOLOGY (2018)
HSD3B1 and Response to a Nonsteroidal CYP17A1 Inhibitor in Castration-Resistant Prostate Cancer
Nima Almassi et al.
JAMA ONCOLOGY (2018)
Relation between plasma trough concentration of abiraterone and prostate-specific antigen response in metastatic castration-resistant prostate cancer patients
E. Carton et al.
EUROPEAN JOURNAL OF CANCER (2017)
Structure-function relationships for the selective inhibition of human 3β-hydroxysteroid dehydrogenase type 1 by a novel androgen analog
Jenny H. Pham et al.
JOURNAL OF STEROID BIOCHEMISTRY AND MOLECULAR BIOLOGY (2017)
Independent Validation of Effect of HSD3B1 Genotype on Response to Androgen-Deprivation Therapy in Prostate Cancer
Neeraj Agarwal et al.
JAMA ONCOLOGY (2017)
High-Dose Abiraterone Acetate in Men With Castration Resistant Prostate Cancer
Terence W. Friedlander et al.
CLINICAL GENITOURINARY CANCER (2017)
N-Myc Induces an EZH2-Mediated Transcriptional Program Driving Neuroendocrine Prostate Cancer
Etienne Dardenne et al.
CANCER CELL (2016)
A Phase II Trial of Abiraterone Combined with Dutasteride for Men with Metastatic Castration-Resistant Prostate Cancer
Rana R. McKay et al.
CLINICAL CANCER RESEARCH (2016)
HSD3B1 and resistance to androgen-deprivation therapy in prostate cancer: a retrospective, multicohort study
Jason W. D. Hearn et al.
LANCET ONCOLOGY (2016)
Redirecting abiraterone metabolism to fine-tune prostate cancer anti-androgen therapy
Zhenfei Li et al.
NATURE (2016)
Transcript-level expression analysis of RNA-seq experiments with HISAT, StringTie and Ballgown
Mihaela Pertea et al.
NATURE PROTOCOLS (2016)
FOXA1 acts upstream of GATA2 and AR in hormonal regulation of gene expression
J. C. Zhao et al.
ONCOGENE (2016)
Enzalutamide Antitumour Activity Against Metastatic Castration-resistant Prostate Cancer Previously Treated with Docetaxel and Abiraterone: A Multicentre Analysis
Klaus Brasso et al.
EUROPEAN UROLOGY (2015)
Molecular Characterization of Enzalutamide-treated Bone Metastatic Castration-resistant Prostate Cancer
Eleni Efstathiou et al.
EUROPEAN UROLOGY (2015)
Conversion of abiraterone to D4A drives anti-tumour activity in prostate cancer
Zhenfei Li et al.
NATURE (2015)
The androgen receptor cistrome is extensively reprogrammed in human prostate tumorigenesis
Mark M. Pomerantz et al.
NATURE GENETICS (2015)
HTSeq-a Python framework to work with high-throughput sequencing data
Simon Anders et al.
BIOINFORMATICS (2015)
RUNX1, an androgen- and EZH2-regulated gene, has differential roles in AR-dependent and -independent prostate cancer
Ken-ichi Takayama et al.
ONCOTARGET (2015)
Emerging mechanisms of resistance to androgen receptor inhibitors in prostate cancer
Philip A. Watson et al.
NATURE REVIEWS CANCER (2015)
Trimmomatic: a flexible trimmer for Illumina sequence data
Anthony M. Bolger et al.
BIOINFORMATICS (2014)
Enzalutamide in Castration-resistant Prostate Cancer Patients Progressing After Docetaxel and Abiraterone
Andres Jan Schrader et al.
EUROPEAN UROLOGY (2014)
No clear evidence of a clinical benefit of a sequential therapy regimen with abiraterone acetate and enzalutamide
Edoardo Francini et al.
EXPERT REVIEW OF ANTICANCER THERAPY (2014)
Therapeutic targeting of BET bromodomain proteins in castration-resistant prostate cancer
Irfan A. Asangani et al.
NATURE (2014)
Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2
Michael I. Love et al.
GENOME BIOLOGY (2014)
A Gain-of-Function Mutation in DHT Synthesis in Castration-Resistant Prostate Cancer
Kai-Hsiung Chang et al.
CELL (2013)
Increased Survival with Enzalutamide in Prostate Cancer after Chemotherapy
Howard I. Scher et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
The androgen receptor fuels prostate cancer by regulating central metabolism and biosynthesis
Charles E. Massie et al.
EMBO JOURNAL (2011)
Abiraterone and Increased Survival in Metastatic Prostate Cancer
Johann S. De Bono et al.
NEW ENGLAND JOURNAL OF MEDICINE (2011)
Molecular Characterization of Neuroendocrine Prostate Cancer and Identification of New Drug Targets
Himisha Beltran et al.
CANCER DISCOVERY (2011)
Integrative Genomic Profiling of Human Prostate Cancer
Barry S. Taylor et al.
CANCER CELL (2010)
3β-Hydroxysteroid Dehydrogenase Is a Possible Pharmacological Target in the Treatment of Castration-Resistant Prostate Cancer
Kristen Evaul et al.
ENDOCRINOLOGY (2010)
Effect of Dutasteride on the Risk of Prostate Cancer.
Gerald L. Andriole et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
The Sequence Alignment/Map format and SAMtools
Heng Li et al.
BIOINFORMATICS (2009)
Development of a Second-Generation Antiandrogen for Treatment of Advanced Prostate Cancer
Chris Tran et al.
SCIENCE (2009)
Plasma Isoflavones and Subsequent Risk of Prostate Cancer in a Nested Case-Control Study: The Japan Public Health Center
Norie Kurahashi et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: Recommendations of the prostate cancer clinical trials working group
Howard I. Scher et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Phase I clinical trial of a selective inhibitor of CYP17, abiraterone acetate, confirms that castration-resistant prostate cancer commonly remains hormone driven
Gerhardt Attard et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Pharmacokinetics and bioavailability of the isoflavone biochanin A in rats
Young Jin Moon et al.
AAPS JOURNAL (2006)
Gene set enrichment analysis: A knowledge-based approach for interpreting genome-wide expression profiles
A Subramanian et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2005)
Determination of rat oral bioavailability of soy-derived phytoestrogens using an automated on-column extraction procedure and electrospray tandem mass spectrometry
LM Mallis et al.
JOURNAL OF CHROMATOGRAPHY B-ANALYTICAL TECHNOLOGIES IN THE BIOMEDICAL AND LIFE SCIENCES (2003)
Share Paper
